Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Transgene Biotek has informed the Bombay Stock Exchange that the Statement of Deviation or Variation under SEBI's Listing Obligations Regulation 32(1) is not applicable to the company for the quarter ending 31st December 2025. This is because the company did not undertake any public issue, rights issue, preferential issue, or Qualified Institutions Placement (QIP) during the reporting period. The filing is a routine regulatory compliance confirmation that there were no capital-raising activities requiring deviation reporting. The company also noted it could not submit the form via XBRL because the system does not allow NIL entries.
This is a NIL/compliance filing with no impact on shareholders or the stock price. It simply confirms that the company did not raise capital from the market during the quarter, so no deviation report is due.